SCHEMBL4348206

SCHEMBL4348206

CSCC1=NN(c2ccc(C)c(C)c2)C(=O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHMT2 P34897 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 7/20 0.43
TDP1 Q9NUW8 5/20 0.43
APEX1 P27695 1/20 0.43
KMT2A Q03164 8/20 0.41
ALDH1A1 P00352 6/20 0.41
MEN1 O00255 5/20 0.41
KDM4E B2RXH2 5/20 0.41
RECQL P46063 1/20 0.41
GAA P10253 6/20 0.40
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CYP1A2 P05177 1/20 0.38
CHRM2 P08172 1/20 0.38
CYP3A4 P08684 1/20 0.38
CHRM1 P11229 1/20 0.38
TSHR P16473 1/20 0.38
PTGS1 P23219 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4345389 0.84 SHMT2 (0.63) SHMT2SMN1; SMN2MAPTTDP1KMT2A
SCHEMBL4334743 0.82 SHMT2 (0.52) SHMT2SMN1; SMN2MAPTTDP1KMT2A
SCHEMBL4350226 0.81 KMT2A (0.45) SHMT2SMN1; SMN2MAPTTDP1KMT2A
SCHEMBL4663211 0.77 MAPT (0.63) SMN1; SMN2MAPTTDP1KMT2AALDH1A1
SCHEMBL29546133 0.77 MAPT (0.63) SMN1; SMN2MAPTTDP1KMT2AALDH1A1
SCHEMBL9379259 0.75 TAAR1 (0.41) SHMT2MAPTTDP1KMT2AALDH1A1
SCHEMBL9379253 0.75 CYP11B1 (0.44) SHMT2MAPTKMT2AALDH1A1MEN1
SCHEMBL4348251 0.75 APP (0.62) SHMT2SMN1; SMN2MAPTTDP1KMT2A
SCHEMBL9382493 0.74 APP (0.46) SHMT2SMN1; SMN2MAPTKMT2AALDH1A1
SCHEMBL4345438 0.72 LOX (0.63) SMN1; SMN2MAPTTDP1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK SHMT2 1330/4885SMN1; SMN2 2310/4885MAPT 4627/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK SHMT2 1330/4885SMN1; SMN2 2310/4885MAPT 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.